Agriculture, from the outset, has been made possible by humans tweaking the genes of plants to make them grow faster, produce ...

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.

Researchers have revealed that so-called “junk DNA” contains powerful switches that help control brain cells linked to ...

· Better growth, better results: Every cell type has its ideal pH — mammalian cells prefer about 7.4, while many plant cells ...

CAMP4 Therapeutics is pioneering the development of antisense oligonucleotides (ASOs) that target regulatory RNAs (regRNAs). These molecules play a crucial role in gene expression and can influence ...

When most of us think of DNA, we have a vague idea it's made up of genes that give us our physical features, our behavioral ...

A tiny percentage of our DNA—around 2%—contains 20,000-odd genes. The remaining 98%—long known as the non-coding genome, or ...

Biotech Addition emerges with $100M from the Gates Foundation to develop next-generation gene therapies for chronic and rare diseases with a new approach The Silicon Review.

But only a tiny percentage of our DNA – around 2% – contains our 20,000-odd genes. The remaining 98% – long known as the non-coding genome, or so-called ‘junk’ DNA – includes many of the switches that ...

Cambridge, USA-based CAMP4 Therapeutics has entered into a strategic research, collaboration and license agreement with UK ...